莎普爱思：收到盐酸奥布卡因滴眼液药品注册证书

Core Viewpoint - The company received the drug registration certificate for Oubkain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant regulatory approval for a product used in ophthalmic surface anesthesia [1] Company Summary - Shapais (603168) announced on October 24 that it has obtained the drug registration certificate for Oubkain Hydrochloride Eye Drops [1] - The eye drops are intended for use in the field of ophthalmology, specifically for surface anesthesia [1]